Skip to search formSkip to main contentSkip to account menu

APR-246

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

PRIMA-1 Analog APR-246

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246.
e14712 Background: The tumor suppressor gene TP53 is the most frequently mutated gene in cancer. Mutant p53 protein is often… 
2018
2018
A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
Background Between 30 and 40% of human breast cancers express a defective tumor suppressor p53 gene. Wild-type p53 tumor… 
2018
2018
Prima-1 a APR-246 v léčbě nádorových onemocnění
Východiska : Nejcastěji mutovaným proteinem u nadorových onemocněni je p53 a jednou z možnosti protinadorove terapie je… 
2017
2017
Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells.
e14098Background: TP53 is the most frequently mutated gene in triple-negative breast cancer, being present in approximately 80… 
2015
2015
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).
TPS5605 Background: p53 mutations are associated with increased chemoresistance. APR-246 is a small molecule that restores mutant… 
2013
2013
Small Molecule Therapeutics PRIMA-1 Met / APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p 73 and Noxa
Targeting p53 by the small-molecule PRIMA-1/APR-246 has shown promising preclinical activity in various cancer types. However… 
2011
2011
Cancer Therapy : Preclinical PRIMA-1 Met / APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p 53
Purpose: Small cell lung cancer (SCLC) is a highly malignant disease with poor prognosis, necessitating the need to develop new… 
2010
2010
Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer
Abstract 1806 The tumor suppressor protein p53 is a transcription factor involved in cell cycle arrest, senescence and apoptosis… 
2010
2010
APR-246, a new class anticancer compound in phase l/lla clinical trials.
TPS183 Background: APR-246 belongs to a new class of small molecules that is currently being tested in a phase I/IIa clinical… 
2009
2009
In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs.
Abstract 2751 Poster Board II-727 Introduction: Mutations of TP53 are associated with an extremely poor prognosis in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)